Pharmexcil warns that President Trump's 25% tariff on Indian goods, effective August 1, will increase the cost of essential drugs in the US. India supplies nearly 47% of US pharmaceutical needs, particularly in generics. Finding alternative sources matching India's scale and affordability will be a daunting challenge, potentially harming US consumers and healthcare systems.